Company intelligence / Profile preview

Kaveri Therapeutics

Naples, Florida, United Stateskaveritherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Kaveri Therapeutics is a U.S.-based clinical-stage oncology biotechnology company formed in 2026 to advance two small-molecule cancer programs spun out from Lupin. The company is focused on biomarker-driven development of targeted therapies for hard-to-treat solid tumors. Its initial pipeline consists of LNP7457, a PRMT5 inhibitor, and LNP8701, a SOS1 inhibitor, both of which have reported early clinical data. Kaveri operates as an independent company, although Lupin remains its majority shareholder and has provided seed funding and exclusive rights to the programs. The company intends to raise additional capital to support global clinical studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

LupinLupin Inc.

Beyond the preview

Go deeper on Kaveri Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaveri Therapeutics.

Explore the full profile